Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-01 in healthy volunteers
NCT06766864Phase 1Completed
- Sponsor
- Dren Bio
- Start
- Mar 2025
- Primary completion
- Aug 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DR-01 (5 arms), sponsored by Dren Bio. Primary endpoint: Treatment-Emergent Adverse Events at 57 days. Started Mar 2025; status: completed.
02
Drugs
DR-01
Beyond the preview
Go deeper on NCT06766864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766864.